Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.
Eli Lilly: obesity-drug scale is now a manufacturing and cash-conversion test
NYSELLYCoverage BootstrapEli Lilly and Company
Thesis summary
Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.